-
Cy5-UTP for Mechanistic RNA Imaging
2026-08-28
Cy5-UTP enables direct fluorescent RNA probe synthesis for FISH, expression analysis, and RNA–protein studies. This guide connects Cyanine 5-uridine triphosphate chemistry with assay design lessons from MALAT1–TDP-43 research.
-
Phosbind Biotin LC: PVDF Workflow Guide
2026-08-28
Phosbind Biotin LC is a phosphate-binding reagent for sequence-independent detection of phosphorylated proteins on PVDF membranes. It is intended for Western Blot workflows using streptavidin-HRP and chemiluminescence, but it is unsuitable for aqueous-only protocols and long-term storage as a working solution.
-
DNase I (RNase-free) for Clean RNA Workflows
2026-08-27
DNase I (RNase-free) supports reliable DNA removal for RNA extraction, RT-PCR, in vitro transcription, and chromatin-focused workflows without introducing RNase activity. This guide combines mechanism, practical starting conditions, controls, and troubleshooting with assay lessons from human sensory-neuron research.
-
DDX21, NAT10, and CRC Metastasis
2026-08-27
This 2025 Cell Death and Disease study identifies a DDX21–SIRT7–NAT10 regulatory axis that increases ac4C modification and stabilizes ATAD2, SOX4, and SNX5 mRNAs in colorectal cancer. The findings connect RNA-binding protein competition with post-transcriptional RNA modification, providing a mechanistic explanation for coordinated metastasis and angiogenesis.
-
Selonsertib (GS-4997) for ASK1 Stress Research
2026-08-26
Selonsertib (GS-4997) gives researchers a selective, ATP-competitive way to test whether ASK1 drives oxidative stress, p38/JNK signaling, inflammation, and fibrosis. This workflow translates kidney-focused lupus nephritis findings into practical cell, tissue, and translational assay strategies while separating target engagement from downstream phenotype.
-
15-PGDH Inhibition Improves Muscle Repair During GLP-1 Loss
2026-08-26
The reference study identifies 15-PGDH inhibition as a way to improve muscle stem cell activity, regenerated myofiber growth, and force recovery during semaglutide-associated weight loss in obese mice. Its central contribution is the demonstration that a 15-PGDH inhibitor can complement GLP-1 receptor agonist therapy without reducing the intended loss of body weight, although translation to human muscle preservation remains untested.
-
In Vitro Drug Response Metrics in Cancer
2026-08-25
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability to separate proliferative arrest from actual cell death during anticancer drug testing. Its central practical contribution is a time- and endpoint-aware framework that can improve interpretation of cytotoxicity, apoptosis-focused assays, and translational response studies.
-
T7 RNA Polymerase for Translational RNA Workflows
2026-08-25
Learn how T7 RNA Polymerase supports reproducible in vitro transcription, from linearized plasmid templates to dual-cargo RNA studies inspired by a recent lung cancer immunotherapy report. This practical guide covers setup, assay design, process controls, and troubleshooting for research-grade RNA synthesis.
-
RNA Pol II Inhibition and Regulated Cell Death
2026-08-24
Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic program rather than simply through progressive loss of transcription, mRNA, and protein. Their functional-genomic analysis identifies loss of hypophosphorylated RNA Pol IIA as the initiating signal, establishing the Pol II degradation-dependent apoptotic response (PDAR) as a framework for interpreting diverse anticancer treatments.
-
FLOT1–FOSL2–EphA2 Axis in Alzheimer’s Microglia
2026-08-24
A 2026 Neuropharmacology study identifies a FLOT1–FOSL2–EphA2 regulatory axis that promotes pro-inflammatory microglial polarization through p38/MAPK signaling in an APP/PS1 model. The findings connect lipid-raft-associated regulation with transcriptional control, neuroinflammation, and spatial memory, while providing a mechanistic framework for evaluating microglial interventions.
-
MLN8237 (Alisertib) Workflow for Aurora A Research
2026-08-23
Build a reproducible Aurora A kinase inhibition workflow with MLN8237 (Alisertib), from DMSO stock preparation and dose–response design to mitotic, apoptotic, and chromatin-level readouts. The strategy also extends into trained-immunity research, where Aurora A inhibition can be connected to SAM metabolism and inflammatory gene regulation.
-
FKBP11 as a Secretory Translocon Accessory Factor
2026-08-22
A 2024 Molecular Biology of the Cell study identifies FKBP11 as a membrane-associated accessory factor of ribosome–translocon complexes in the endoplasmic reticulum. Its selective association with ribosomes translating proteins with long translocated regions, together with reduced stability of EpCAM and PTTG1IP after depletion, supports a cotranslational role for FKBP11 in secretory-protein biogenesis.
-
HBTU for Peptide Probe Synthesis
2026-08-22
HBTU combines rapid carboxylic acid activation with a comparatively low racemization risk, making it a practical choice for assembling enzyme-responsive peptide probes. This workflow connects solid phase peptide synthesis to luminescent immunoproteasome assays, with specific guidance for stock preparation, coupling control, purification, and troubleshooting.
-
OLIG2 smRNA for Rapid hiPSC Oligodendrocyte Differentiation
2026-08-21
Xu et al. developed a non-integrating synthetic modified mRNA approach that uses the OLIG2S147A variant to drive rapid differentiation of human induced pluripotent stem cells into oligodendrocyte progenitors. The reference study established a six-day delivery workflow that produced more than 70% NG2-positive progenitors, which matured into functional oligodendrocytes and promoted remyelination in vivo.
-
Omeprazole (A2845): Practical Research Guide
2026-08-20
Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, antiulcer activity study design, and related assay development. It is intended for scientific workflows only and should not be used for diagnosis, treatment, or other clinical purposes.